Onglyza saxagliptin regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 10-2 that Bristol-Myers and AstraZeneca have provided sufficient evidence to rule out an unacceptable amount of cardiovascular risk as...